Christopher Cabell

Christopher H.
Cabell is Chief Executive Officer at Corhepta Pharmaceuticals, Inc. since 2024.
Dr. Cabell is Director at ScienceMedia, Inc. since 2020.
Dr. Cabell is Independent Director at Pulmatrix, Inc. since 2020.
Dr. Cabell is a Member of the American College of Cardiology Foundation.
Dr. Cabell is President & Head-Research & Development at Inhibikase Therapeutics, Inc. starting 2025.
Formerly, Dr. Cabell was Chief Medical Officer & Executive Vice President at Zura Bio Ltd. from 2023 to 2024.
Dr. Cabell was Chief Medical Officer & Head-Clinical Development at Emergent BioSolutions, Inc. from 2021 to 2023.
Dr. Cabell was Chief Medical Officer, Head-Research & Development at Arena Pharmaceuticals, Inc. in 2020.
Dr. Cabell was Senior VP & Head-Therapeutic Delivery Unit at Quintiles Transnational Corp.
from 2015 to 2017.
Dr. Cabell was Chief Medical & Scientific Officer at Quintiles, Inc. (California) from 2007 to 2017.
Dr. Cabell was Chief Medical & Scientific Officer at IQVIA RDS, Inc. from 2007 to 2017.
Dr. Cabell was Chief Medical & Scientific Officer at IQVIA, Inc. Formerly, Dr. Cabell was Director at Cenduit LLC.
Dr. Cabell was Director-Echocardiography Core Lab at Duke Clinical Research Institute.
Dr. Cabell was Co-Chairman at Cardiac Safety Research Consortium.
Dr. Cabell was Co-Chairman at US Food & Drug Administration.
Dr. Cabell was Associate Professor at Duke University School of Medicine.
Education includes graduate degree from Duke University, undergraduate degree from The Pennsylvania State University, and doctorate from Duke University School of Medicine.